Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies. AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need - Â Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consistently across the comprehensive clinical program - Â Erenumab is the first and only fully human monoclonal antibody of its kind, uniquely designed to specifically block the CGRP receptor, which plays a critical role in activation of migraine The digital press release with multimedia content can be accessed here: Â Â Â Â Â Â Â Â Â Â Â Â - Novartis today announced new analyses across a spectrum of patients building a clear picture of the potential of AMG 334 (erenumab) for migraine prevention. The data, being presented at the 18th Congress of the International Headache Society (IHC, Vancouver, Canada), add to the consistent efficacy and safety results to date, and also cover quality of life, burden of disease and health economic topics relating to migraine. A new analysis from a pivotal Phase II study shows erenumab reduced monthly migraine days in patients with chronic migraine for whom previous preventive treatments have failed. New data in a cardiovascular population with stable angina, reaffirming erenumab's safety profile, is also being presented at IHC.
